Company Announcement no. 14/2009 To: NASDAQ OMX Copenhagen Hørsholm, Denmark, August 12,2009 LifeCycle Pharma's Updated Financial Calendar 2009 LifeCycle Pharma A/S (OMX: LCP) issues today an updated financial calendar for - 009: nd August 20, 2009: Interim Report for 2 Quarter - for the period ending June 30, 2009. (Changes from publication after end of business day on August 19, 2009 to the morning of August 20, 2009, 9:00 AM CET due to board travelling arrangements). rd November 11, 2009: Interim Report for 3 Quarter - for the period ending September 30, 2009 (unchanged). For more information, please contact: LifeCycle Pharma A/S Dr. Jim New Peter Schøtt Knudsen President & CEO Head of Investor Relations +45 70 33 33 00; jsn@lcpharma.com +45 20 55 38 17: psk@lcpharma.com About LifeCycle Pharma A/S (LCP) Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low‐scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol‐lowering product, Fenoglide™, currently on the U.S. market and a diversified near‐ and medium‐term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com. LifeCycle Pharma A/S Kogle Allé 4 DK‐2970 Hørsholm CVR no. 26 52 77 67 Company Announcement no. 14/2009